Global Non-Invasive Prenatal Testing Market is expected to grow at a healthy rate of 16% to reach $9 billion by 2026
Non-invasive prenatal testing (NIPT), is a method of determining the risk of whether the fetus of the mother will be born with certain genetic abnormalities. NIPT is a safe and highly effective way of screening for conditions such as Down syndrome, Edwards syndrome, Patau syndrome, monosomy X, and Turner syndrome.
Currently, there is two types of NIPT methods
that are commercially available, massive parallel sequencing (MPS) technology
and the single-nucleotide polymorphism (SNP) based method.
Rapid Shift towards Cell-Free DNA screening
The Discovery
of cell-free DNA (cfDNA)-based NIPT has created a rapid shift in the paradigm
of aneuploidy screening during pregnancy. It’s a simple blood test that can be
performed during pregnancy. Clinical validation studies suggest that NIPT is more
accurate than combined first-trimester screening (CFTS), with very high
sensitivity (99.3%) and specificity (99.9%) for trisomy 21(Down syndrome). NIPT
is also safer than other invasive diagnostic techniques such as chorionic
villus sampling and amniocentesis, which involves a risk of miscarriage (0.1–0.2%).
Advent of Advanced Technologies for NIPT Products
The advent of next-generation sequencing
technology has enabled the sequencing of fetal DNA fragments that
can be assembled into a full genetic map, allowing the fetal genome to be
scanned prenatally and non-invasively. Developments in molecular technologies
and the discovery of cell-free fetal DNA in maternal plasma have also led to
novel screening methods for fetal chromosomal aneuploidies.
Currently, various types of
NIPT tests are available in the market such as Panorama, Vistara, MaterniT
GENOME, Harmony Test, among others which help in the screening of chromosomal abnormalities
developing in the fetus. Moreover, several developments have been made to
impact the quality of care for expectant mothers such as:
- In January 2022, QIAGEN entered into collaborations with Atila BioSystems to provide non-invasive prenatal testing (NIPT) solutions to QIAGEN’s dPCR franchise.
- In June 2021, Illumina and Next-generation Genomic Thailand announced the launch of next-generation sequencing (NGS)-based VeriSeq NIPT Solution v2 in the country which helps to detect anomalies missed by targeted assays.
“Prenatal care is a dynamic and continuously evolving field. Development in new molecular technologies and the discovery of cell-free fetal DNA are fueling groundbreaking advancements to improve care for mother and child and to offer parents reproductive options.”- Senior Director, Head of Research & Product Development, Sequencing & Array-based Company, United States
Some of the key challenges restricting the growth of the
non-invasive prenatal testing market are stringent government regulations, and limitations
of NIPT such as despite its high accuracy, it is still considered a screening
test.
Geographic Overview: NIPT Market
North
America is the largest market for NIPT with >45% revenue share, followed by
Europe. The growing prevalence of genetic disorders in newborns associated with
increasing maternal age, wider adoption, and the presence of leading players working
on fetal and neonatal care in this region are some of the key factors driving
the North America market.
The
market in Europe is expected to grow
significantly over the forecast period due to the adoption of the latest
technology, new product launches, and a strong reimbursement framework for
these tests in the region. The Asia Pacific region is expected to witness the highest
CAGR in the coming years.
Competitive Landscape Analysis:
Non-Invasive Prenatal Testing Market
Some of the prominent
players operating in the global NIPT market are Agilent Technologies, BGI
Genomics, Cradle Genomics, Berry Genomics, Sequenom, Roche (Ariosa
Diagnostics), among others.
Get Customized Research Report on Non-Invasive Prenatal Testing (NIPT) Market
@ https://meditechinsights.com/non-invasive-prenatal-testing-market/
Comments
Post a Comment